About the Company
adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ADVM News
ADVM Stock Earnings: Adverum Biotechnologies Beats EPS for Q4 2023
ADVM stock results show that Adverum Biotechnologies beat analyst estimates for earnings per share the fourth quarter of 2023.More From InvestorPlace The #1 AI Investment Might Be This Company You’ve ...
Adverum Biotechnologies (ADVM) Receives a Buy from TD Cowen
In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Adverum Biotechnologies (ADVM – Research Report). The ...
Adverum Biotechnologies: Q4 Earnings Snapshot
REDWOOD CITY, Calif. — REDWOOD CITY, Calif. — Adverum Biotechnologies Inc. (ADVM) on Monday reported a loss of $23.7 million in its fourth quarter. On a per-share basis, the Redwood City, ...
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD - - Completed ...
Adverum Biotechnologies Awaits Court Decision on Settlement
Adverum Biotechnologies (ADVM) has released an update. The Delaware Court of Chancery scheduled a hearing on April 9, 2024, to consider a proposed settlement in the stockholder derivative action ...
This Biotech Stock Plunged 20% but Wall Street Expects a 195% Recovery
With the pandemic largely in the rear-view mirror, vaccine maker Novavax has seen shares fall. Yet, analysts have high hopes ...
Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier
Voyager Therapeutics investors need to be patient as the biotech targets hard to treat Alzheimer's and Parkinson's. Read why ...
Stocks on the Launchpad: The Next 3 Market Sensations
In the current bullish stock market, it’s an exhilarating period for savvy investors betting on the upcoming market ...
Biotech VCs See Room for More Growth in Obesity Drug Market
Biotech VCs See Room for More Growth in Obesity Drug Market ...
Edwards Lifesciences Corporation
View Edwards Lifesciences Corporation EW stock quote prices, financial information, real-time forecasts, and company news from CNN.
Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent ...
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent ...
Loading the latest forecasts...